Safety and Effectiveness of Bone Marrow Cell Concentrate in the Treatment of Chronic Critical Limb Ischemia Utilizing a Rapid Point-of-Care System

Table 2

Cell product characterization.

	Preprocessed (mean ± SD)	Postprocessed (mean ± SD)
TNCC ()	2.64 ± 1.29	8.04 ± 3.65
MNCC ()	0.59 ± 0.26	2.16 ± 1.02
CD34+ve ()	1.33 ± 2.09	4.05 ± 3.81
Cell viability (%)	72.02 ± 19.73	88.94 ± 5.54
Potency
Total CFUs ()	ND	101.1 ± 113.61
Sterility	No growth	No growth

fold increase in postprocessed sample is about 3x.